Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Accumulated Expenses (2016 - 2025)

Voyager Therapeutics' Accumulated Expenses history spans 11 years, with the latest figure at $9.1 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 35.85% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $9.1 million, down 35.85%, while the annual FY2025 figure was $9.1 million, 35.85% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $9.1 million at Voyager Therapeutics, down from $15.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $15.0 million in Q3 2025 and bottomed at $2.2 million in Q1 2024.
  • The 5-year median for Accumulated Expenses is $7.5 million (2022), against an average of $7.9 million.
  • The largest annual shift saw Accumulated Expenses tumbled 70.13% in 2022 before it surged 302.71% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $5.0 million in 2021, then surged by 55.64% to $7.8 million in 2022, then decreased by 15.38% to $6.6 million in 2023, then surged by 114.26% to $14.2 million in 2024, then crashed by 35.85% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Accumulated Expenses are $9.1 million (Q4 2025), $15.0 million (Q3 2025), and $6.3 million (Q2 2025).